Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Safety and Efficacy of Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy for Relapsed/Refractory B-Cell Lymphoma

NCT07546630 is registered in ClinicalTrials.gov with Affiliated Hospital to Academy of Military Medical Sciences as lead sponsor.

NCT NCT07546630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07546630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Safety and Efficacy of Nanobody-Based CD19/CD20 Tandem Dual CAR-T-cell Therapy for Relapsed/Refractory B-Cell Lymphoma
Lead sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
May 1, 2029
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory b-cell lymphoma